Jefferies London: BeOne Medicines announced a phase 3 success for its HER2 bispecific today in gastric cancer. John Olyer walks us through that and the whole pipeline
He hit on earnings, the HER2, degraders, and what BeOne is looking for in potential partners.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.